In this DNB//Back Bay Healthcare Capital Markets podcast episode, Jim Cirenza, Head of Fixed Income and Equities at DNB, Kristoffer Braaten, Director and Head of Equity Capital Markets at DNB, and Vasilios Kofitsas, Partner and Managing Director of Investment Banking at Back Bay Life Science Advisors, review the performance of the healthcare markets in 2024, offering insights into what 2025 could bring. With a detailed analysis of market trends, IPO activities, and investor behaviors, they evaluate the past year's challenges and the cautious optimism prevailing in the sector as the new year unfolds. As well, there's an emphasis on the importance of European investor engagement for companies looking to list in the U.S. market.

Learn more about the DNB//Back Bay Partnership and read our disclosures here.

The topic of bispecific antibodies has been an area of interest in the pharma space for a long time now. The recent news of the notable late-stage data from Akeso and Summit’s PD-1/VEGF bispecific antibody ivonescimab to treat non-small cell lung cancer that has captured the industry writ large encouraged us to revisit the topic.

To date, there have been ten bispecific antibody approvals in oncology, seven of which are for hematological malignancies. Recently, there has been more traction in development pipelines for solid tumors. Most bispecific antibody approvals are currently or projected to be above the $1M annual revenue threshold.

Podcast topics include:

• The biologics of a bispecific antibody
• The benefits of a bispecific antibody compared to autologous therapies
• The buzz around Akeso and Summit’s PD-1 VEGF bispecific antibody asset
• The broad state of bispecifics in approved products and development pipelines
• The potential of trispecifics, bispecific conjugates and beyond

In this DNB//Back Bay Healthcare Capital Markets Episode, Vasilios Kofitsas, Partner and Managing Director at Back Bay Life Science Advisors speaks with Jim Cirenza and Kristoffer Braaten of DNB Bank in New York. They focus on key drivers affecting markets this year and discuss the recent news of the Fed’s decision to cut interest rates by 50-basis points.

Topics in the podcast include:

• After two difficult years, the appearance of a healthy market rotation since July
• The Fed’s decision mid-September to cut rates by 50 basis points
• Healthcare IPOs: historical and recent activity – is the window opening?
• An outlook including headwinds and tailwinds that may impact the healthcare sector

We welcome listener questions and/or topics you’d like to learn more about.

You can listen to previous episodes here or submit your inquiries here.

Learn more about the DNB//Back Bay Partnership and read our disclaimers at https://www.bblsa.com/dnb-back-bay-partnership.